ANAB Paul F Lizzul sells $58K worth of shares
Sep 24, 2024, 9:33 PM
7.40%
What does ANAB do
AnaptysBio, a clinical-stage biotechnology company based in San Diego, focuses on immune cell modulators and has two checkpoint agonists in Phase 2 trials for autoimmune diseases. The company went public on January 26, 2017, and employs 117 staff.
Paul F Lizzul sold 1,500 shares of ANAB on 23 September at $38.67 per share, worth a total of $58K. They now own 15,398 ANAB shares, or a 9% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.